Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
Highest Quality | For Research Use Only

PNC-27

Buy PNC-27 Peptide Czech Republic

PNC-27 is a peptide that has gained notable attention in the field of oncology for its potential anti-cancer properties. This peptide was derived from the p53 tumor suppressor protein and is designed to interact with cell membranes selectively, causing the death of cancer cells while leaving healthy cells untouched.

The mechanism of action of PNC-27 involves the binding to HDM-2 proteins, which are overexpressed in cancerous cells. Upon this interaction, it forms membrane pores leading to cell lysis and apoptosis — a form of programmed cell death. Research suggests this targeted approach minimizes the risk of collateral damage to healthy cells, a common pitfall of conventional chemotherapy regimens. Research on PNC-27 is still in its early stages, but initial studies show promise.

Showing all 3 results

Potential Benefits of PNC-27 Peptide

  • Antitumor Efficacy: According to research studies, PNC-27 demonstrates significant antitumor efficacy, especially in cells expressing HDM2, a protein often overexpressed in many types of cancer [1].
  • Enhanced Chemotherapy Effectiveness: Scientific studies indicate it could potentially be used to enhance the effectiveness of chemotherapy drugs like liposomal doxorubicin, leading to better therapeutic outcomes [1].
  • Synergistic Effect with Other Drugs: In vitro studies have shown a synergistic effect between PNC-27 and paclitaxel, another chemotherapy agent. Research suggests PNC-27 has the ability to eliminate cells that survive paclitaxel treatment, potentially improving survival rates [2].
  • Potential Treatment for Resistant Ovarian Cancer: PNC-27 research shows promise as an alternative treatment for ovarian cancer, including cases that have developed resistance to conventional treatment methods [3].
  • Use in Targeted Delivery Systems: PNC-27 studies indicate it can be used in targeted delivery systems for gene therapies, such as survivin-shRNA and SN38, against colon adenocarcinoma [4].
  • Enhanced Cytotoxicity with Ketone Bodies: Research suggests acetoacetate, a ketone body, can enhance the cytotoxicity of PNC-27 on MCF-7 breast cancer cells. This highlights the potential benefits of ketogenic diets for cancer therapy when combined with PNC-27 [5].
  • Reduced Risk of Toxicity and Side Effects: According to research, peptides like PNC-27 do not accumulate in specific organs, reducing the risk of toxicity and side effects commonly associated with traditional cancer treatments [6].
  • Inhibition of Tumor Cell Proliferation: Research also indicates that PNC-27 could play a role in inhibiting tumor cell proliferation and enhancing the efficacy of other anti-cancer agents [7].

Please note that PNC-27 is a research peptide and whilst it holds promise, more extensive clinical trials are needed to fully understand its potential benefits and risks.

References

[1] https://pubmed.ncbi.nlm.nih.gov/28565974/

[2] https://www.gynecologiconcology-online.net/ article/S0090-8258(14)00542-3/fulltext

[3] https://pubmed.ncbi.nlm.nih.gov/28667027/

[4] https://www.sciencedirect.com/science/ article/abs/pii/S1773224722000892

[5] https://faseb.onlinelibrary.wiley.com/ doi/abs/10.1096/fasebj.2019.33.1_supplement.lb231

[6] https://jbiomedsci.biomedcentral.com/ articles/10.1186/s12929-017-0328-x

[7] https://www.mdpi.com/2227-9059/11/9/2515

 

ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Direct Peptides website: https://czech-republic.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.